



Tibor Hortobágyi

Contact

Tibor Hortobágyi

Publications (2)

Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. *BMC cancer* 2024; 24:82.

Shaw C, Shaw P, Robberecht W, Van Damme P, Veldink J, Van den Berg L, Ticozzi N, Taroni F, Gellera C, Silani V, Kirby J, Pall H, Morrison K, Al-Chalabi A, Weale M, Brown R, Landers J, Andersen P, Baas F, Vianney de Jong J, de Bellerocche J, Morris A, Asbroek A, Schelhaas H, Scott K, Troakes C, Lee Y, Miller J, Johnson L, Topp S, Vance C, Shatunov A, Newhouse S, Jones A, Gray I, Wright J, Nestor P, Weber M, Sapp P, Lovestone S, Lupton M, Powell J, Rogelj B, Al-Sarraj S, Hortobágyi T, Smith B. The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. *Eur J Hum Genet* 2012; 21:102-8.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch